Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Intracranial Hemorrhage: A Devastating Outcome of Congenital Bleeding Disorders--Prevalence, Diagnosis, and Management, with a Special Focus on Congenital Factor XIII Deficiency

(2018) Intracranial Hemorrhage: A Devastating Outcome of Congenital Bleeding Disorders--Prevalence, Diagnosis, and Management, with a Special Focus on Congenital Factor XIII Deficiency. Seminars in Thrombosis and Hemostasis.

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Intracranial hemorrhage (ICH) is a medical emergency. In congenital bleeding disorders, ICH is a devastating presentation accompanied with a high rate of morbidity and mortality. The prevalence of ICH is highly variable among congenital bleeding disorders, with the highest incidence observed in factor (F) XIII deficiency (FXIIID) (∼30). This life-threatening presentation is less common in afibrinogenemia, FVIII, FIX, FVII, and FX deficiencies, and is rare in severe FV and FII deficiencies, type 3 von Willebrand disease and inherited platelet function disorders (IPFDs). In FXIIID, this diathesis most often occurs after trauma in children, whereas spontaneous ICH is more frequent in adults. About 15 of patients with FXIIID and ICH die; the bleeding causes 80 of deaths in this coagulopathy. Although in FXIIID, the bleed most commonly is intraparenchymal (> 90), epidural, subdural, and subarachnoid hemorrhages also have been reported, albeit rarely. As this life-threatening bleeding causes neurological complications, early diagnosis can prevent further expansion of the hematoma and secondary damage. Neuroimaging plays a crucial role in the diagnosis of ICH, but signs and symptoms in patients with severe FXIIID should trigger replacement therapy even before establishment of the diagnosis. Although a high dose of FXIII concentrate can reduce the rate of morbidity and mortality of ICH in FXIIID, it may occasionally trigger inhibitor development, thus complicating ICH management and future prophylaxis. Nevertheless, replacement therapy is the mainstay of treatment for ICH in FXIIID. Neurosurgery is performed in patients with FXIIID and epidural hematoma and a hemorrhage diameter exceeding 2 cm or a volume of ICH is more than 30 cm 3. Contact sports are not recommended in people with FXIIID as they can elicit ICH. However, a considerable number of safe sports and activities have been suggested to have more benefits than dangers for patients with congenital bleeding disorders, and are hence suitable for these patients. © 2018 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Item Type: Article
Keywords: blood clotting factor 13 concentrate, Article; bleeding disorder; blood clotting factor 13 deficiency; brain hemorrhage; disease severity; epidural hematoma; human; morbidity; mortality rate; neuroimaging; neurosurgery; priority journal; subarachnoid hemorrhage; subdural hematoma; substitution therapy; blood clotting disorder; blood clotting factor 13 deficiency; brain hemorrhage; complication; prevalence, Blood Coagulation Disorders, Inherited; Factor XIII Deficiency; Intracranial Hemorrhages; Prevalence
Page Range: pp. 267-275
Journal or Publication Title: Seminars in Thrombosis and Hemostasis
Volume: 44
Number: 3
Publisher: Thieme Medical Publishers, Inc.
Identification Number: 10.1055/s-0037-1604109
ISSN: 00946176
Depositing User: مهندس جمال محمودپور
URI: http://eprints.muk.ac.ir/id/eprint/1878

Actions (login required)

View Item View Item